Ruxolitinib for Chronic Graft-versus-Host Disease. Reply

N Engl J Med. 2021 Oct 21;385(17):1631-1632. doi: 10.1056/NEJMc2113499.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Graft vs Host Disease* / drug therapy
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Humans
  • Nitriles
  • Pyrazoles / therapeutic use
  • Pyrimidines

Substances

  • Nitriles
  • Pyrazoles
  • Pyrimidines
  • ruxolitinib